Nicox Provides Third Quarter 2022 Financial and Business Highlights
Press Release Nicox Provides Third Quarter 2022 Financial and Business HighlightsTopline results of the NCX 470 Mont Blanc Phase 3...
COVID-19
Microbot Medical Accomplishes the Next-Step in the Regulatory Process for the LIBERTY® Robotic System
HINGHAM, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), announced that it has submitted the anticipated...
Eterna Therapeutics to Present at iPSC-Derived Immunotherapies Congress
SAN DIEGO, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a biopharmaceutical company...
SteraMist to be Used in a Global Influenza Vaccine Facility in Australia
Company Continues To See Strong Bookings and A Robust Pipeline For Its Custom Engineered Systems in The Life Science SectorFREDERICK,...
Recce Pharmaceuticals Announces Preclinical SARS-CoV-2 Study Update
Figure 1 SARS-COV-2 50% Tissue Culture Infectious Dose (TCID50) measurement in response to treatment with R327 in Syrian golden hamsters....
Comera Life Sciences Announces Favorable Preclinical Results of Lead SQore Excipient in SEQURUS-2 Study
WOBURN, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing...
Aerovate Therapeutics Presents Novel Phase 2b/Phase 3 IMPAHCT Trial Design at CHEST Annual Meeting 2022
Adaptive and efficient trial design may allow for expedited development timeline while maintaining scientific rigorWALTHAM, Mass., Oct. 18, 2022 (GLOBE...
Vir Biotechnology Announces First Patient Dosed in Groundbreaking Phase 2 Trial of VIR-2482 for Antibody Prophylaxis of Influenza A
– First clinical trial evaluating the role of a monoclonal antibody in preventing seasonal flu – – Announcement follows recent...
Phathom Pharmaceuticals to Present Latest Data on Vonoprazan at American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting
FLORHAM PARK, N.J., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing...
Prelude Therapeutics Receives FDA Clearance of IND for PRT3789, a Potent and Selective First-in-Class SMARCA2 Protein Degrader
Phase 1 Study Will Include Biomarker Selected Patients with Advanced Solid TumorsWILMINGTON, Del., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Prelude...
TOWER ONE WIRELESS ANNOUNCES THIRTEEN TOWERS COMPLETED – ADDITIONAL NON-CANCELLABLE RENT OF $ 2,300,000
TOWER ONE CONSTRUCTION UPDATE FOR THE MONTH OF SEPTEMBER 2022VANCOUVER, BC, CANADA, Oct. 18, 2022 (GLOBE NEWSWIRE) -- TOWER ONE...
Aligos Therapeutics to Present Data on pan-Coronavirus Protease Inhibitors for the Treatment of COVID-19 at Cambridge Healthtech Institute’s 20th Annual Discovery on Target Conference, to be Held October 17-20, 2022 in Boston, MA
Aligos’ pan-Coronavirus inhibitor, ALG-097558, is on track to begin first clinical studies in 1H 2023SOUTH SAN FRANCISCO, Calif., Oct. 18,...
Chiesi USA Chosen as One of Fortune’s 25 Best Small and Medium Workplaces in Biotechnology and Pharmaceuticals
Chiesi USA recognized for its dedication to ensuring that employee voices are heard and valuedCARY, N.C., Oct. 17, 2022 (GLOBE...
Exagen Announces Appointment of John Aballi as CEO
SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), announced today that the company has appointed John...
Sorrento Successfully Completes Phase 1 Study and Is Proceeding to Implement Global Registrational Trials with STI-1558, an Oral Mpro Inhibitor as a Standalone Oral Treatment and Prevention of COVID-19 without the Need for a Ritonavir Booster
Phase 1 Study (with 58 healthy volunteers) of STI-1558 was completed in Australia with 300 mg, 600 mg, 1,200 mg...
Small Pharma Reports Fiscal Second Quarter 2023 Highlights
Last patient dosed in Phase IIa trial for lead product candidate, SPL026 with supportive therapy for the treatment of Major...
NeuBase Therapeutics Announces Strategic Restructuring Focused on Advancing Its Platform in Gene Editing
Workforce reductions of ~60% and implementation of a robust cost reduction plan are expected to extend the Company’s cash runway...
electroCore Provides Select Third Quarter 2022 Financial Guidance
ROCKAWAY, N.J., Oct. 14, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today...
Biofrontera Inc. Adopts Limited Duration Shareholder Rights Plan
WOBURN, Mass., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the...
Novan and EPI Health, a Novan Company, Announce Abstracts Accepted for Poster Presentation at the 42nd Annual Fall Clinical Dermatology Conference®
DURHAM, N.C., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN) and EPI Health, a...